Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.
Int J Pharm. 2021 Jul 15;604:120738. doi: 10.1016/j.ijpharm.2021.120738. Epub 2021 May 26.
The main objective of the study was to determine if rodent housing conditions, specifically housing climate, could impact the in vivo performance of poly(lactide-co-glycolide) (PLGA) microspheres through temperature modification of the subcutaneous space. Vivitrol®, a once monthly naltrexone injectable suspension, was chosen as a model PLGA microparticle formulation for this study. Two lots of Vivitrol were used to ascertain any potential differences that may exist between the batches and if in vitro characterization techniques could delineate any variation(s). The pharmacokinetics of the naltrexone-PLGA microparticles were determined in the rodent model under two different housing climates (20 vs. 25 °C). The results demonstrate that such difference in housing temperature resulted in a change in subcutaneous temperature but actually within a narrow range (36.31-36.77 °C) and thus minimally influenced the in vivo performance of subcutaneously injected microparticles. The shake-flask method was used to characterize the in vitro release at 35, 36, and 37 °C and demonstrated significant differences in the in vitro release profiles across this range of temperatures. Minimal differences in the in vitro characterization of the two lots were found. While these results did not provide statistical significance, the local in vivo temperature may be a parameter that should be considered when evaluating microparticle performance. The IVIVCs demonstrate that in vitro release at 37 °C may not accurately represent the in vivo conditions (i.e., subcutaneous space in rodents), and in certain instances lower in vitro release temperatures may more accurately represent the in vivo microenvironment and provide better correlations. Future studies will determine the extent temperature and specifically co-housing, may have on the relative impact of the in vivo performance of injectable polymeric microparticles based upon the significant differences observed in the in vitro release profiles across the range of 35-37 °C.
研究的主要目的是确定啮齿动物的饲养条件,特别是饲养环境,是否可以通过改变皮下空间的温度来影响聚(丙交酯-乙交酯)(PLGA)微球的体内性能。Vivitrol®,一种每月一次的纳曲酮注射混悬剂,被选为这项研究的模型 PLGA 微球制剂。使用了两个批次的 Vivitrol,以确定批次之间是否存在任何潜在差异,以及体外特性分析技术是否可以描述任何差异。在两种不同的饲养环境(20°C 和 25°C)下,在啮齿动物模型中确定了纳曲酮-PLGA 微球的药代动力学。结果表明,饲养温度的差异导致皮下温度发生变化,但实际上变化范围很窄(36.31-36.77°C),因此对皮下注射微球的体内性能影响极小。使用摇瓶法在 35°C、36°C 和 37°C 下对体外释放进行了特征描述,结果表明在该温度范围内体外释放曲线存在显著差异。在这两个批次的体外特性方面发现了微小的差异。虽然这些结果没有提供统计学意义,但局部体内温度可能是评估微球性能时应考虑的一个参数。IVIVC 表明,在 37°C 下的体外释放可能无法准确代表体内条件(即啮齿动物的皮下空间),在某些情况下,较低的体外释放温度可能更准确地代表体内微环境并提供更好的相关性。未来的研究将确定温度,特别是共同饲养,在多大程度上可能对基于在 35-37°C 范围内观察到的体外释放曲线的显著差异的注射型聚合物微球的体内性能产生相对影响。